opioid-containing analgesic — Competitive Intelligence Brief

opioid-containing analgesic (opioid-containing analgesic) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: opioid-containing analgesic. Area: Pain management.

phase 3 opioid-containing analgesic opioid receptors Pain management Small molecule

Target snapshot

opioid-containing analgesic (opioid-containing analgesic) — Rutgers, The State University of New Jersey. Opioid-containing analgesics work by binding to opioid receptors in the brain and spinal cord, altering the perception of and response to pain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
opioid-containing analgesic TARGET	opioid-containing analgesic	Rutgers, The State University of New Jersey	phase 3	opioid-containing analgesic	opioid receptors
SAMIDORPHAN L-MALATE	SAMIDORPHAN L-MALATE		marketed	Atypical Antipsychotic [EPC]	dopamine and serotonin type 2 (5HT2) receptors, opioid receptors	2021-01-01
BENZHYDROCODONE	BENZHYDROCODONE		marketed	Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic	Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways	2018-01-01
NALBUPHINE HYDROCHLORIDE	NALBUPHINE HYDROCHLORIDE		marketed		kappa opioid receptors, mu opioid receptors	1979-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
ropivacaine,morphine chloride,epinephrine,ketorolac	ropivacaine,morphine chloride,epinephrine,ketorolac	Jose Antonio Bernia Gil	marketed	Multimodal analgesic combination (local anesthetic + opioid + NSAID + sympathomimetic)	Sodium channels (ropivacaine), mu-opioid receptors (morphine), alpha/beta-adrenergic receptors (epinephrine), cyclooxygenase 1 and 2 (ketorolac)
Norco 5milligram-325milligram Tablet	Norco 5milligram-325milligram Tablet	Wake Forest University Health Sciences	marketed	Opioid analgesic combination	Opioid receptors (mu, delta, kappa); COX inhibition (acetaminophen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (opioid-containing analgesic class)

1. Rutgers, The State University of New Jersey · 1 drug in this class